Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...
For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted to the intensive care unit ...
GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.
Doctors are alerted by digital clubbing, a bulbous swelling of fingertips, a sign known since ancient times. This often ...
The 3TR project aims to transform the understanding and treatment of immune-mediated diseases, with its core principles in ...
Anti-IL5 therapy significantly reduces moderate and severe exacerbations in asthma and COPD, preventing major ...
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...
GSK and Empirico ink license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases: London, UK Wednesday, October 29, 2025, 09:00 Hr ...
The respiratory medical community is moving toward shared decision-making in self-managing chronic respiratory disease, but ...
Verywell Health on MSN
8 Common Causes of Shortness of Breath When Walking Short Distances
Shortness of breath when walking short distances can occur suddenly or be a chronic condition. It should be evaluated, as it ...
Researchers uncovered how lung cells decide whether to rebuild tissue or fight infection. This built-in “switch” may be the ...
Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback